Business Wire

CYNORA

20.1.2021 07:02:08 CET | Business Wire | Press release

Share
CYNORA Announces Availability of Industry’s First Device Test Kits for TADF Deep Green Emitters for Next-Generation OLED Displays

Marking a new innovation trajectory for the OLED industry, CYNORA today announced that device test kits for its Thermally Activated Delayed Fluorescence (TADF)-based Deep Green emitter for next-generation OLED displays are now available to customers. The development is an industry-first milestone for TADF technology, and validates CYNORA’s roadmap commitment.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210119006159/en/

Known as the cyUltimateGreen™, the product delivers efficiency of more than 20 percent, which meets current industry specifications of 150cd/A in top emission devices. It demonstrates lifetime of 400h LT95@15mA, and color point and spectra that match today’s DCI-P3 standard. In addition, the product shows compatibility with BT2020, a color standard that requires greater color purity than DCI-P3, and one that will significantly enlarge the color depth.

The milestone delivers a materials technology breakthrough that will help display manufacturers unleash the full efficiency potential of new-generation OLEDs and catalyze game-changing OLED products. It starts with TADF Deep Green and will soon include a TADF Deep Blue solution.

The cyUltimateGreen Emitter: A “Brightness” Booster for Next-Generation OLEDs

Within the OLED stack is the emissive layer. This is where the light is made. Within the layer are Red, Green and Blue pixels. By combining all three, the full color gamut is rendered in the display. The Green pixel influences brightness. It accounts for as much as 25 percent of the OLED stack costs.

CYNORA’s CEO, Adam Kablanian, commented: “We set out to innovate a differentiated new technology that would enable display leaders to leapfrog beyond legacy emitter solutions for next-generation OLEDs. We believed that TADF was the most promising approach. We knew that with the right blend of advanced technologies and chemistry expertise, the breakthrough was achievable. Our talented team has confirmed the commercial capability of the TADF emitter technology, which has the ability to offer customers substantial savings. The kits are now ready for customer testing and verification.”

GEM: CYNORA’s Materials Discovery Advantage

Behind the cyUltimateGreen product is CYNORA’s Generative Exploration Model (GEM). GEM is the materials discovery engine pioneered by CYNORA to identify with extreme precision the most relevant and useful molecules, and related combinations, from an infinite source of chemical molecules.

GEM combines two key elements: artificial intelligence (AI) and the brainpower of CYNORA’s chemists. While AI offers immense computational capabilities, there can be prediction errors and other uncertainties that diminish the output of useful data for specialized applications. GEM supercharges AI for OLED materials discovery by pairing its computing power with the materials expertise and OLED device knowledge of CYNORA’s chemists to identify molecules with high potential. From there, a scoring system predicts how closely the molecule conforms to must-have parameters, as well as its usefulness for the target purpose – in this case, high-efficiency emitter materials.

GEM strengthened CYNORA’s discovery and synthesis capabilities, and fast-tracked completion of the cyUltimateGreen product, said CTO, Dr. Jan Richter. “Given that the universe of chemical molecules is infinite, identifying the most relevant molecules is exceedingly tough,” he said. “While AI gives us a powerful discovery acceleration tool, our imperative isn’t just to find molecules that are a theoretical fit; they must also be chemically synthesizable. That’s where CYNORA’s chemistry expertise provides the value add.”

The expertise extends to CYNORA technologists’ deep knowledge of the full OLED device. This helped the company engineer the cyUltimateGreen to meet mass-production requirements, without requiring display leaders to make expensive alterations to their manufacturing lines. Essential details like matching evaporation temperatures to meet current device architectures, and aligning material parameters (like energy levels), were part of the calculations. To further reduce cost, integration factors were also considered, like how to manufacture the product within existing hardware and process frameworks without requiring extra evaporation chambers.

Richter added: “TADF technology is igniting a new innovation trajectory for OLED emitter materials. We’re excited to lead with our cyUltimateGreen product.”

For information on CYNORA GmbH, please visit www.cynora.com

cyUltimateGreen is a trademark of CYNORA GmbH

Social Media:

https://facebook.com/cynoragmbh

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release

Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release

Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye